(Accessed 9 September 2017)
Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
The cost-effectiveness of quadrivalent vaccine programmes is an open question. The original analysis that supported the paediatric programme only considered a trivalent live attenuated vaccine (LAIV). The cost-effectiveness of the QIIV to other patients has not been established. We sought to estimate the cost-effectiveness of these programmes, establishing a maximum incremental total cost per dose of quadrivalent vaccines over trivalent vaccines.
Dominic Thorrington, Edwin van Leeuwen, Mary Ramsay, Richard Pebody and Marc Baguelin
Published on: 8 September 2017